Ciblage du récepteur du facteur de croissance épidermique et applications en cancérologie ORL [Targeting of epidermal growth factor receptor and applications in ORL cancer].

Détails

ID Serval
serval:BIB_ED20DA2112B6
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Ciblage du récepteur du facteur de croissance épidermique et applications en cancérologie ORL [Targeting of epidermal growth factor receptor and applications in ORL cancer].
Périodique
Bulletin du Cancer
Auteur(s)
Tortochaux J., Aunoble B., Rolhion C., Bourhis J.
ISSN
0007-4551 (Print)
ISSN-L
0007-4551
Statut éditorial
Publié
Date de publication
2003
Volume
90
Numéro
Spec No
Pages
S220-S227
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review Publication Status: ppublish
Résumé
EGFR (epidermal growth factor receptor) is a transmembrane glycoprotein highly expressed in head and neck squamous cell carcinoma (HNSCC). Once triggered by ligands, tyrosine kinase located at their inner part is phosphorylated, initiating signal transduction pathways towards the nucleus. Two categories of EGFR inhibitors are affordable: the former group includes monoclonal antibodies whereas the latter regards tyrosine kinase inhibitors (ITK). Acting more as cytostatic than cytotoxic agents, they may potentiate both chemotherapy (CT) and radiation therapy (RT). Characterized by a spectrum of toxicity that does not overlap that of CT or RT, they may be associated with these treatments. First clinical trials have demonstrated the feasibility of their administration. Side-effects merely consist of skin reactions and digestive symptoms; their intensity is generally mild and they resolve at the completion of treatment. As of yet, response rates are sometimes astounding but are still disparate. Randomized studies are ongoing. A better definition of EGFR status is warranted. Other data regarding interactions between her-family members, ligands parameters and the cascade regulation of signal transduction would certainly enable to better define the clinical applications of this new therapeutical approach.
Mots-clé
Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents/therapeutic use, Carcinoma, Squamous Cell/drug therapy, Humans, Morpholines/therapeutic use, Neoplasm Proteins/antagonists & inhibitors, Otorhinolaryngologic Neoplasms/drug therapy, Protein-Tyrosine Kinases/antagonists & inhibitors, Pyrimidines/therapeutic use, Pyrroles/therapeutic use, Quinazolines/therapeutic use, Receptor, Epidermal Growth Factor/antagonists & inhibitors
Pubmed
Création de la notice
01/12/2014 17:56
Dernière modification de la notice
20/08/2019 16:15
Données d'usage